These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27797596)

  • 1. Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.
    Cuenca-Lopez F; Rivero A; Rivero-Juárez A
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):105-112. PubMed ID: 27797596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.
    German P; Mathias A; Brainard D; Kearney BP
    Clin Pharmacokinet; 2016 Nov; 55(11):1337-1351. PubMed ID: 27193156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):572-5. PubMed ID: 26524329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
    Brieva T; Rivero A; Rivero-Juarez A
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
    German P; Moorehead L; Pang P; Vimal M; Mathias A
    J Clin Pharmacol; 2014 Nov; 54(11):1290-8. PubMed ID: 24925712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Abaalkhail F; Elsiesy H; Elbeshbeshy H; Shawkat M; Yousif S; Ullah W; Alabbad S; Al-Jedai A; Ajlan A; Broering D; Saab S; Al Sebayel M; Al-Hamoudi W
    Transplantation; 2017 Nov; 101(11):2739-2745. PubMed ID: 28795982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
    Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
    Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 13. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
    Thokala P; Simpson EL; Tappenden P; Stevens JW; Dickinson K; Ryder S; Harrison P
    Pharmacoeconomics; 2016 Aug; 34(8):741-50. PubMed ID: 26892974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
    Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
    Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
    J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
    Gamal N; Andreone P
    Expert Opin Drug Saf; 2016; 15(4):549-57. PubMed ID: 26899025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
    Brown AN; Liu L; Rodriquez JL; Zhao L; Schuster L; Li E; Wang GP; Neely MN; Yamada W; Drusano GL
    Sci Rep; 2017 Oct; 7(1):14421. PubMed ID: 29089577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir.
    German P; Mathias A; Brainard DM; Kearney BP
    Clin Pharmacokinet; 2018 Nov; 57(11):1369-1383. PubMed ID: 29644537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.